Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership - Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application

Adaptimmune Appoints Elliot Norry as

Chief Medical Officer and Makes Changes to R&D Leadership

- Organizational changes strengthen scientific

and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic

candidates and trials -

and OXFORDSHIRE, United Kingdom, January 13, 2020 -- Adaptimmune

Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. Elliot Norry as

Senior Vice President and Chief Medical Officer (CMO) effective immediately, and additional changes to its R&D organization.

"Elliot has done a fantastic job as acting CMO over the

past few months. This builds on his impact leading the ADP-A2AFP program in liver cancer as well as leading our safety and pharmacovigilance

team over the last four years. I look forward to continuing to work with Elliot to deliver cell therapy treatments to patients

with cancer," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "In addition, we have made changes

to our R&D leadership to accelerate how our products move from research to late stage development, including rapid application

of translational learnings that are crucial to bringing cell therapies to patients."

Dr. Norry has served as Head of Clinical Safety and Pharmacovigilance

and leader of the ADP-A2AFP program since 2015. He has been acting Chief Medical Officer since August 2019. Prior to joining Adaptimmune,

he served as Safety Development Leader and was Chair of the Hepatic Safety Panel at GSK. Prior to his work in the biotech and

pharmaceutical industries, Dr. Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania

for 13 years. He holds a B.A. from Columbia College and an M.D. from New York University. He performed his residency in Internal

Medicine at Temple University Hospital, Philadelphia and GI fellowship at Thomas Jefferson University Hospital, Philadelphia.

Changes to the R&D Leadership that will strengthen

the end-to-end scientific and clinical development from early to late stage, include:

More information about Adaptimmune's R&D leaders

can be found here on the Leadership Team page.

Adaptimmune is a clinical-stage biopharmaceutical company focused

on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide

Enhanced Affinity Receptor) T-cell platform enables the engineering

of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.

Adaptimmune Forward-Looking Statements

This release contains "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain

risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated

by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities

and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization

processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from

those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our

Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 6, 2019, and our other

SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made

and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

S bastien Desprez - VP, Communications and Investor

Juli P. Miller, Ph.D. - Senior Director, Investor Relations